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Abstract Heterotrimeric G proteins are involved in hormonal 
signal transduction across the plasma membrane. Recent evi- 
dence suggests that they have a role in vesicular protein transport 
as well. Biochemical probes that interfere with the classical G 
protein cycle have been applied to the field of intracellular mem- 
brane transport to study their mechanism of action. Evidence has 
been obtained that intracellular G proteins act both through clas- 
sical and alternative G protein cycles. 
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1. Classical heterotrimeric G protein cycle at the plasma 
membrane 
Many hormones and neurotransmitters elicit cellular re- 
sponses by binding to cell-surface receptors. Most of these 
receptors at the plasma membrane have a common feature in 
that they contain seven membrane spanning domains (reviewed 
in [1,2]). Stimulation of these receptors results in the activation 
of guanine nucleotide-binding regulatory proteins (G proteins) 
[3-5]. The proteins of this family have a heterotrimeric struc- 
ture; The a subunit hat binds and hydrolyses GTP, and a fl-and 
~'-subunit which form a stable fly-dimer. The binding of an 
agonist o an appropriate receptor catalyzes the exchange of 
GDP for GTP on the G protein a subunit (Fig. 1). This is 
followed by dissociation of GTP-bound G o from the fly dimer. 
Both the activated ~ subunit and the fly subunit can interact 
with effectors and modulate their activity [6]. Hydrolysis of 
GTP by the a subunit returns the protein into its basal confor- 
mation and the subunits re-associate. Regulatory mechanisms 
are superimposed on this very general scheme which allows 
either a very specific or a pleiotypic response to agonist stimu- 
lation [5]. 
Several biochemical probes are available which interfere with 
the G protein cycle and can be used to study the role of G 
protein-coupled signal transduction cascades in cellular path- 
ways. Fig. 1 summarizes some of these modulators and their 
proposed mechanism of action. For discussions on the precise 
mechanism of action of these modulators the reader is referred 
to the references. GTPyS, a non-hydrolyzable analogue of GTP 
can bind and thus activate all GTP binding proteins. In con- 
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trast, A1F 4 only activates heterotrimeric G proteins [7]. Other 
probes such as G protein derived peptides, Pertussis toxin and 
mastoparan (and analogues) interfere with coupling of a recep- 
tor to the C-terminus of a heterotrimeric G protein. Pertussis 
toxin (PTX) catalyzed ADP-ribosylation of a cysteine within 
the C-terminus of Gi or Go [8] and synthetic C-terminal Go 
peptides [9,10] interfere with the binding of a G protein to its 
receptor (uncoupling) and thus prevent G protein activation. 
Peptides corresponding to specific regions of the cytoplasmic 
domains of receptors appear to be able to activate G proteins 
[11]. Mastoparan, a peptide toxin from wasp venom presuma- 
bly mimics this cytosolic loop and interacts with the C-terminus 
of a Gi/Go protein [12,13] resulting in its activation. A logical 
consequence is that the effect of mastoparan can be reversed 
by PTX treatment of G proteins. Since A1F 4 directly activates 
heterotrimeric G proteins without nucleotide exchange, bypass- 
ing the requirement for a receptor to stimulate GDP release 
from G proteins, A1F; can still activate G proteins that are 
uncoupled from their receptor by e.g. ADP-ribosylation with 
PTX. 
In addition, peptides affecting the interaction of G proteins 
with specific effectors have been developed [14]. These peptides 
are difficult o design, however, since effectors can interact with 
various regions of the G protein [15,16]. Recently, purified G~ 
and fly subunits as well as overexpression of constitutively 
active mutants of G~ have been used to demonstrate heir in- 
volvement in signaltransduction cascades [17,18]. 
2. Heterotrimeric G proteins at intracellular organdies 
Although the classical signaltransduction cascade as de- 
scribed in Fig. 1 operates at the plasma membrane, it has been 
known for some time that heterotrimeric G proteins are found 
on intracellular membranes as well. Pertussis-toxin sensitive G 
proteins have been detected on membranes of secretory gran- 
ules [19], the endoplasmic reticulum [20,21], endosomes [22] and 
the Golgi complex [23]. 
The localization of G proteins to subcellular organelles raises 
the interesting question whether intracellular G proteins func- 
tion within signaltransduction cascades imilar to those at the 
plasma membrane or whether alternative, as yet undefined 
roles for heterotrimeric G proteins exist. For example, most of 
the receptors containing seven membrane spanning domains 
that couple to G proteins are found at the plasma membrane 
[1,2]. If intracellular G proteins do not participate in the classi- 
cal signalling cascade, one could expect hat probes, affecting 
the interaction between G proteins and these receptors (Fig. 1) 
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Fig. 1. Probes affecting the G protein cycle. The G protein cycle is based 
on [5]. Rather than showing the actual target of the probes (e.g. G,, for 
CTX), the presumed site of action (e.g. inhibition of GTP hydrolysis 
for CTX) of the probes is indicated. For details, see text. Not shown 
is the G, subunit-specificity of the probes: the effect of mastoparan is 
relativelv soecific for G.,/G_ 1121. Pertussis toxin ADP-ribosvlates G._/ 
G,,JG,, s&units whereas &oieri toxin is specific for G,, [8]. &F; bin& 
directly to G, (bypassing nucleotide exchange). The presence of GDP 
and AlF; in the nucleotide binding pocket of G, mimics the active, 
GTP-bound G, conformation [16,78]. Abbreviations: C-peptides, pep- 
tides corresponding to the carboxyl-terminus of G,; E-peptides, effec- 
tor-peptides, corresponding to the region of G, that interacts with 
down-stream targets; R-peptides, receptor-peptides corresponding to 
specific regions of the cytoplasmic domains of receptors capable of 
activating G proteins; CTX, cholera toxin; PTX, pertussis toxin. 
are ineffective in uncoupling intracellular G protein cycles. Sev- 
eral lines of evidence now suggest hat (some of the) intracellu- 
lar G proteins are involved in membrane trafficking along the 
endocytic and secretory pathways. Indications for both classi- 
cal as well as non-classical G protein cycles will be discussed. 
3. Heterotrimeric G proteins in vesicular protein transport 
Over the past decade, a protein machinery has been discov- 
ered which is necessary for vesicular transport of proteins from 
one compartment o the other (reviewed in [24]). Elucidation 
of this protein machinery started with the finding that protein 
transport between organelles can occur in cell-free systems [25] 
and has since been expanded to numerous in vitro assays that 
reconstitute the major intracellular protein transport pathways 
[26]. The first indications that heterotrimeric G proteins might 
be part of this protein machinery date back to the late 1980s 
in which it was shown that AlF, inhibits several reconstituted 
transport pathways along the secretory and endocytic path- 
ways [27-291. Since AlF; activates heterotrimeric G proteins 
but not monomeric, small molecular weight GTP binding pro- 
teins [7], these results could be taken as a first indication for the 
involvement of heterotrimeric G proteins, although AlF, can 
interact with other proteins as well [30]. The current view on 
G protein sensitive transport pathways is summarized in Fig. 
2. Evidence for the involvement of specific sub-types of G 
proteins in membrane transport pathways will be discussed 
briefly (for other reviews, see also [31,32]). 
Overexpressed Gal_? in LLC-PK, cells co-localizes to the 
Golgi complex and inhibits transport of a secretory protein 
(heparan sulfate proteoglycan) through the Golgi complex re- 
sulting in an accumulation of its precursors in the medialltrcms- 
Golgi. This effect is reversed by pertussis toxin treatment of the 
cells [33]. Similarly, in polarized cells, transport to the baso- 
lateral membrane is also inhibited by a Gai-subtype [34]. In 
addition to the effect of G,,.1 at the Golgi complex, this G 
protein also is involved in stimulation of exocytosis (see below). 
The G,-subclass of G proteins has been shown to affect 
various intracellular pathways. Peptides, derived from the do- 
main of receptors that couple to G,, mastoparan analogues with 
specificity for G,, as well as cholera toxin activate G,, resulting 
in inhibition of endosome fusion [35]. This is in an apparent 
paradox with the inhibition of endosome fusion by /?y which 
supposedly inactivates G proteins but could be explained if a 
second heterotrimeric G protein is involved to whichBy specif- 
ically binds [36]. In this model activation of Gsa results in free 
/3y which associates with the second G protein. With the recent 
identification ofpy as a signalling molecule [6], it could how- 
ever also transduce signals in and of itself. Alternatively, the 
inhibition is an indirect effect due to the interaction with ARF 
(see below). In polarized cells, G,, affects both transcytosis as 
well as transport from the TGN to the apical membrane. In 
contrast to endosome fusion, activation of G,, stimulates tran- 
scytotic vesicle production from early endosomes destined for 
the apical membrane [17] as well as transport of proteins from 
the TGN to the apical membrane [34]. In addition, both path- 
ways are inhibited by antibodies directed against the amino- 
terminal but not carboxyl-terminal region of G,,. Given these 
remarkable similarities, it cannot be excluded that apical trans- 
port also occurs via an intermediate compartment such as an 
endosomal compartment [17]. In this case, the effect of G,, in 
transcytosis and in apical transport would be on the same 
transport pathway. namely from the endosomal compartment 
to the apical membrane. 
The [runs-Golgi network (TGN) is an interesting subcom- 
partment in that multiple heterotrimeric G proteins have been 
localized to this organelle which affect vesicle budding [37,38]. 
Both cholera toxin sensitive G proteins (G,,, activation of 
which stimulates vesicle production) as well as pertussis toxin 
sensitive G proteins (GJG,,, activation of which inhibits vesi- 
cle production) affect the formation of TGN-derived vesicles 
[38]. The fact that AIF,, an effector that activates both classes 
at the same time, gives an overall inhibition of vesicle produc- 
tion could be explained by the higher abundance of G,,/G,, 
over G,, at the TGN [38]. Interestingly, a cytosolic 
phosphoprotein has been identified that antagonizes the inhibi- 
tion of vesicle production by AlF, [39]. It is therefore proposed 
that the phosphoprotein either inhibits the G,,/G,, class of G 
proteins or stimulate G,,. Both membrane transport pathways 
departing from the TGN, constitutive secretory vesicles 
and immature granules (destined for regulated secretion) are 
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Fig. 2. Involvement of heterotrimeric G proteins in intracellular t ans- 
port pathways. A polarized cell is depicted in order to be able to show 
all pathways affected by heterotrimeric G proteins. The data are com- 
piled, however, both from non-polarized and polarized cells. For de- 
tails, see references in text. The effect of A1F~ in receptor-mediated 
endocytosis is described by Carter et al. [79]. Abbreviations: ER, endo- 
plasmic reticulum; SG, secretory granules; TGN, trans-Golgi network; 
E, endosomal compartment. 
affected equally by toxins and probes affecting G protein activ- 
ity [381. 
In summary, one G protein subtype can either stimulate or 
inhibit vesicular protein transport, depending on the transport 
pathway. The transport pathways discussed so far fulfill the 
requirements of a classical G protein cycle such as reversal of 
the effect of mastoparan [38] or Go overexpression [33] by PTX 
as depicted in Fig. 1. Below, some indications for non-classical 
G protein cycles will be discussed. 
4. Indications for non-classical G protein cycles 
Vesicular protein transport between the ER and Golgi com- 
plex is inhibited by A1F4, mastoparan and fl), subunits [40]. 
However, the inhibition by mastoparan is not reversed by PTX 
[40] although both probes act on the same class of G/Go pro- 
teins [8,12]. PTX treatment of cells does not affect transport of 
the VSV-G protein from the ER to the medial-Golgi [40] 
whereas PTX stimulates ecretion at the medial/trans Golgi 
[33]. Thus, in early stages of protein transport, probes interfer- 
ing with G protein cycles do not behave as expected in a classi- 
cal G protein cycle (Fig. 1) and therefore, alternative G protein 
cycles might be involved. One has to be cautious about the 
introduction of artifacts due to the use of amphiphilic peptides 
such as mastoparan [41]. Reversal of the effect of mastoparan 
by PTX is indicative for a specific interaction of mastoparan 
with a G/Go protein. However, if the effect of mastoparan is
not reversed by PTX, this does not indicate a non-specific effect 
of mastoparan per se, as will be discussed next. 
In exocytosis (regulated secretion) both classical and non- 
classical G protein cycles seem to operate. Exocytosis from 
several cells such as adrenal chromaffin cells can be dissected 
into an ATP-dependent priming step and a calcium-dependent 
secretion step [42-44]. It is beyond the scope of this review to 
discuss exocytosis n detail, but the emerging picture is that two 
heterotrimeric G proteins act in series in the exocytotic path- 
way. Go~, localized to the chromaffin granules [45] seems to be 
involved in the priming step. G~.3, localized to the plasma 
membrane is involved in the calcium-dependent (fusion) step. 
G~_3 fulfills the requirements for involvement in a classical G 
protein cycle. Activation of G~.3 by secretagogues that mimic 
receptor activation (i.e. interaction with G proteins via the 
C-terminal region of G proteins) is reversed both by synthetic 
peptides that correspond to the C-terminus of G~_3 and by 
antibodies directed against this region [46]. In addition, the 
activation of a G protein in the calcium-dependent stage (pre- 
sumably G~_3) with mastoparan is reversed by pertussis toxin 
treatment [47]. Finally, receptor-mimicking peptides, pre-acti- 
vated Gi/Go proteins, as well as transient expression of active 
mutants of Gi/Go inhibited the calcium-dependent step of ex- 
ocytosis [18]. In contrast, the G protein involved in the ATP- 
dependent priming step is likely subject o a non-classical mech- 
anism of activation. Activation of this G protein by mastoparan 
results in inhibition of secretion which can not be reversed by 
PTX [47]. The inhibition is reversed, however, by antibodies 
directed against he C-terminus of Go~ [48]. For Go~ an alterna- 
tive mechanism of activation has been described. Growth-cone- 
associated protein (GAP-43) can activate Go~ in its depalmi- 
toylated (cytosolic) form [49,50]. Interestingly, GAP-43 mimics 
the action of mastoparan and inhibits the priming reaction. 
Like mastoparan, the inhibition of GAP-43 is reversed by anti- 
bodies directed against he C-terminus of Go [51]. 
There has been much speculation that G proteins involved 
in vesicular transport interact with ADP-ribosylation factor 
(ARF) [31,52]. ARF is a small GTP-binding protein involved 
in various membrane transport pathways [24,52]. Speculation 
on the interaction of a G protein with ARF is based on the 
initial discovery of ARF, in which it was shown that ARF is 
a necessary component in the CTX-stimulated ADP-ribosyla- 
tion of Gs~ [53]. In addition, A1F~ stimulates binding of ARF 
and coatomer to Golgi membranes [54,55], although A1FT~ can- 
not activate ARF itself [7]. Furthermore, purified f13/subunits 
inhibit ARF binding to Golgi membranes [54]. This however, 
can now also be explained by the recent finding that GDP- 
bound ARF can interact directly with fly [56] rather than indi- 
cating the involvement of a heterotrimeric G protein. Thus, an 
alternative interpretation of the inhibitory effect of added fly 
would be the interaction with cytosolic (GDP-bound) ARF 
which prevents binding to Golgi membranes. In addition, this 
could implicate that the effect of addition of exogenous fly on 
several membrane transport pathways [17,36,37,40] cannot be 
taken anymore as conclusive vidence for the involvement of 
a heterotrimeric G protein. It remains to be established whether 
the GDP-bound ARF-fly interaction has physiological signifi- 
cance. First of all, fly resides in membranes rather then cytosol 
and only GTP-bound ARF is bound to membranes [7,54,57]. 
Second, the interaction is relatively weak and more likely re- 
flects the fact that among all small GTP binding proteins, ARF 
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has the highest homology to G~-subunits [58]. It does add 
support o the speculation that If-COP might be the subunit of 
coatomer that binds to ARF [59,60]. fl'-COP contains the WD- 
repeat consensus sequence which is also found in Gfl (reviewed 
in [61]). 
Two types of proteins, fl-COP (part of the coatomer com- 
plex) and p200 (a phosphoprotein) dissociate from the Golgi 
complex in the presence of Brefeldin A (BFA) [62,63]. BFA is 
a fungal metabolite that inhibits an enzyme in a Golgi-enriched 
fraction that catalyses guanine nucleotide (GDP-GTP) ex- 
change on ARF protein [64,65]. This BFA effect indicates the 
involvement of ARF in membrane binding of fl-COP and of 
p200. Membrane binding of both proteins is induced by GTPyS 
and A1F4 [54,66]. Interestingly, pertussis toxin pretreatment of
Golgi membranes to selectively inactivate G~_3, reduced the 
mastoparan-induced binding of p200 to Golgi membranes. 
Stimulation of membrane-binding offl-COP is less sensitive to 
mastoparan and the effect could not be reversed by PTX. Re- 
cently, p200 has been localized to the TGN [67] whereas fl-COP 
operates in early steps of the secretory pathway (reviewed in 
[24]). Thus, there is an interesting parallel with the effect of 
mastoparan and PTX on protein transport in which different 
effects where observed between early and late stages of the 
secretory pathway (see above) and adds further support o the 
hypothesis that non-classical G protein cycles operate at early 
membrane transport pathways. It is of note that we have also 
found that fl-COP binding to Golgi membranes i insensitive 
to PTX treatment of Golgi membranes (J.B.H., unpublished) 
but it is in conflict with data presented by Ktistakis et al. [68]. 
In addition to Gs, G~ and Go proteins found on intracellular 
membranes, a new type of cholera toxin sensitive Go has been 
identified which localizes to the TGN [69]. In addition to the 
highly homologous Gs~ sequence, it contains a 51 kDa N- 
terminal extension resulting in an 'extra large' (XL) G~. Al- 
though its function is unknown, this protein only occurs in cells 
containing both the constitutive and regulated pathway of pro- 
tein secretion. It will be of interest o determine whether this 
extra N-terminal domain contains enzymatic activity: another 
large G protein (Gh) mediates receptor stimulation of phospho- 
lipase C activity but also contains GTPyS-sensitive transglu- 
taminase activity [70]. Apparently, receptor-stimulated GTP- 
binding switches the function of Gh~ from transglutamination 
to receptor signalling [70]. Alternatively, the XL G~ could re- 
flect a covalent coupling of a G protein to a receptor-like 
activity which allows a more potent and productive agonist- 
dependent signal transduction pathway [71]. 
5. Emerging concepts 
5.1. Targeting of G~ subunits to intracellular membranes 
It has become clear that G proteins are found not only at the 
plasma membrane but on intracellular membranes as well. 
Using immuno-fluorescence and/or immuno-EM it appears 
that one subclass of G~ subunit can be detected on several 
membranes that varies between cells [72]. For example, depend- 
ing on the cell-type, G~i_3 is localized exclusively to the Golgi 
complex [33] or to the plasma membrane as well [46]. Changes 
in subcellular localization of overexpressed Gi~-2/G~i_3 chimeras 
suggest hat the targeting information is contained in the car- 
boxyl-terminus of G~ subunits [73]. This agrees well with the 
discovery of a Gc~i_2 with an alterative spliced carboxyl-terminal 
region which changes its cellular distribution from the plasma 
membrane to the Golgi complex [74]. In contrast o retention 
mechanisms ofmembrane-spanning proteins to the Golgi com- 
plex [75] very little is known about the specific targeting of 
peripheral proteins to the Golgi or other subcellular compart- 
ments. But given the fact that the subcellular distribution of G 
proteins varies between different cell-types, it seems more likely 
that G proteins are retained in an organelle due to its interac- 
tion with receptor-type and/or effector-type molecules. This 
would also explain the targeting information residing in the 
carboxyl-terminal region. Variations in expressions of receptor/ 
effector type molecules between cell-types thus result in varia- 
tions of the subcellular localization of G proteins. In agreement 
with this model is has been found that a modest (three-fold over 
endogenous) overexpression f G~_3 results in correct argeting 
to the Golgi complex whereas a high level of overexpression f 
G~i_ 3 subunits results in mistargeting of the G=i_ 3 and as a result 
it is found throughout the cell. This indicates a saturable target- 
ing process [33]. 
5.2. Classical versus non-classical G protein cycles 
Membrane transport pathways near the plasma membrane 
such as endosome fusion, transcytosis and budding of vesicles 
from the TGN seem to involve the classical G protein cycle. It 
is known that receptors containing seven membrane-spanning 
domains can be endocytosed and recycled to the plasma mem- 
brane [76,77], it remains to be established whether intracellular 
organelles that are connected to the plasma membrane by 
transport pathways, can apply this as a potential mechanism 
of activation of intracellular G proteins. In the early stages of 
exocytosis (priming) it seems plausible that a non-classical G
protein cycle operates which involves Go~ and GAP-43. Could 
a similar non-classical G protein cycle operate in early stages 
of the constitutive secretory pathway? Overexpression f Go~_~, 
but not Go~_2, in C6 glial cells results in a very punctuate subcel- 
lular labeling reminiscent of transport vesicles (Bockaert and 
Homburger, pers. commun.) In addition, the constitutive secre- 
tion of only a subset of proteins is affected by the overexpres- 
sion of Go~.l (Bockaert and Homburger, pers. commun). 
The classical G protein cycle at the plasma membrane isvery 
cell-type specific, since cells usually express only a subset of the 
components of the G protein cycle. It is likely that similar 
variations affect the function of intracellular G proteins in 
intracellular membrane transport pathways. Now that the in- 
volvement of G proteins in vesicular protein transport is well 
established, the stage is set to determine their mode of action 
which requires identification of receptor- and effector-type 
molecules, keeping in mind a cell-type specific environment. 
This will yield new insights not only in the mechanism of vesic- 
ular protein transport, but of signal transduction cascades in 
general. 
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